Get the Stockscreener App
141.07
3.26%
-4.76
After Hours:
141.07
Illumina Inc stock is traded at $141.07, with a volume of 1.89M.
It is down -3.26% in the last 24 hours and up +6.77% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$145.83
Open:
$145.25
24h Volume:
1.89M
Relative Volume:
1.09
Market Cap:
$21.56B
Revenue:
$4.28B
Net Income/Loss:
$1.26B
P/E Ratio:
17.87
EPS:
7.8957
Net Cash Flow:
$943.00M
1W Performance:
+5.00%
1M Performance:
+6.77%
6M Performance:
+44.78%
1Y Performance:
+1.00%
1-Day Range:
$139.79
$145.80
1-Week Range:
$134.36
$151.34
52-Week Range:
$68.70
$153.06
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
141.07 | 22.28B | 4.28B | 1.26B | 943.00M | 7.8957 |
|
TMO
Thermo Fisher Scientific Inc
|
618.86 | 227.87B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
238.37 | 165.99B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
713.35 | 56.89B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
148.52 | 41.32B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
242.41 | 41.42B | 15.90B | 1.28B | 2.21B | 7.2842 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jul-11-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-04-25 | Reiterated | Citigroup | Neutral |
| Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Illumina and PREMIA partner to expand clinical access to CGP in Asia - ANTARA News
Cathie Wood’s ARK ETF Buys Intellia, Personalised Stock; Sells Illumina By Investing.com - Investing.com Canada
Cathie Wood’s ARK ETF Buys Intellia, Personalised Stock; Sells Illumina - Investing.com
Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report? - sharewise.com
Illumina names former NIH official as medical chief; commercial chief joins Quanterix - Seeking Alpha
Non-Invasive Prenatal Testing Market is expected to generate a revenue of USD 9.83 Billion by 2031, Globally, at 17.01% CAGR: Verified Market Research® - GlobeNewswire Inc.
Former NIH genomics director Eric Green to join Illumina as CMO - statnews.com
Precision Trading with Illumina Inc. (ILMN) Risk Zones - Stock Traders Daily
Will Illumina Inc. stock split again soon2025 EndofYear Setup & Free High Accuracy Swing Entry Alerts - ulpravda.ru
Can Illumina Inc. stock sustain revenue growthQuarterly Profit Review & Long-Term Safe Return Strategies - ulpravda.ru
Illumina Inc. Stock Underperforms Thursday When Compared To Competitors - 富途牛牛
Is Illumina Inc ILU stock a momentum leaderJuly 2025 Big Picture & Fast Gaining Stock Strategy Reports - moha.gov.vn
What makes Illumina Inc. (ILU) stock appealing to growth investorsJuly 2025 Recap & Weekly Momentum Picks - ulpravda.ru
Illumina, Inc. Appoints Eric D. Green as Chief Medical Officer, Effective February 2, 2026 - MarketScreener
Is It Time To Reassess Illumina (ILMN) After Its Recent Share Price Rebound - Yahoo Finance
China Bans Illumina Sequencer Imports as Trade Tensions Rise - MSN
Biochips Market to Reach US$ 38.53 Billion by 2033, Growing at - openPR.com
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Illumina launches cloud-based platform for multiomic data analysis - Investing.com
Illumina launches cloud-based platform for multiomic data analysis By Investing.com - Investing.com India
Illumina launches powerful software for connected, intuitive, and scalable multiomic analysis - Illumina
DNA Test Kits Market Booming with Rapid Growth Through 2033 |Devyser, Illumina, Inc., Living DNA Ltd - openPR.com
Why Illumina (ILMN) Is Up 6.5% After Advancing Grail Divestiture Plan And What's Next - Yahoo Finance
Next Generation Sequencing (NGS) Market to Reach US$ 35.92 - openPR.com
Illumina’s Crossroads: Genomics Pioneer Tests Investor Patience As Wall Street Reassesses The Stor - AD HOC NEWS
Generali Asset Management SPA SGR Has $2.11 Million Stock Position in Illumina, Inc. $ILMN - MarketBeat
Forecast Cut: Is Illumina Inc stock a smart buy before Fed meetingTrade Exit Summary & AI Based Trade Execution Alerts - moha.gov.vn
Illumina Shares Slip After Citi Issues Bearish Rating Ahead of Earnings - MSN
Illumina (NASDAQ:ILMN) Lowered to "Hold" Rating by Zacks Research - MarketBeat
Illumina Inc.: Can the Genomics Pioneer Reinvent Itself for the AI Era? - AD HOC NEWS
Illumina (NASDAQ:ILMN) Lowered to "Hold" Rating by Wall Street Zen - MarketBeat
Aug Macro: Is Illumina Inc stock dividend yield sustainable2025 Valuation Update & Entry Point Confirmation Signals - moha.gov.vn
Who Owns Illumina? Top Shareholders and Recent Insider Trades - TIKR.com
Biomarker Discovery Market to Reach US$ 54.19 Billion by 2033 - openPR.com
273,111 Shares in Illumina, Inc. $ILMN Purchased by VIRGINIA RETIREMENT SYSTEMS ET Al - MarketBeat
Earnings Are Growing at Illumina (NASDAQ:ILMN) but Shareholders Still Don't Like Its Prospects - 富途牛牛
Illumina stock at a crossroads: genomics giant tests investor patience as Wall Street recalibrates e - AD HOC NEWS
Here's Why Illumina (ILMN) is a Strong Momentum Stock - Yahoo Finance
Japan Nucleic Acid Isolation and Purification Market is Driven - openPR.com
Illumina Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
ILLUMINA INC (NASDAQ:ILMN) Shows Bull Flag Setup Ahead of Potential Breakout - Chartmill
Illumina, Inc. $ILMN Shares Bought by Cwm LLC - MarketBeat
Pacer Advisors Inc. Acquires New Position in Illumina, Inc. $ILMN - MarketBeat
Voya Investment Management LLC Has $5.23 Million Stock Holdings in Illumina, Inc. $ILMN - MarketBeat
United states DNA Forensics Market to Reach USD 5.60 Billion - openPR.com
Take Profit: Is Illumina Inc. stock undervalued vs historical averagesJuly 2025 Short Interest & AI Driven Price Predictions - moha.gov.vn
Swedbank AB Grows Position in Illumina, Inc. $ILMN - MarketBeat
Life Science Instruments & Consumables Market to Reach USD - openPR.com
Genomics in Cancer Care Market to Reach USD 72.87 Billion by 2033 | - openPR.com
Illumina Inc. Stock Underperforms Tuesday When Compared To Competitors - 富途牛牛
Genomics Market Outlook: Market to Reach US$ 118.2 Billion - openPR.com
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.12%
0.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):